Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H19FN2O3 |
Molecular Weight | 342.3642 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N[C@@H]1CN(C(=O)C1)C2=CC=C(OCC3=CC(F)=CC=C3)C=C2
InChI
InChIKey=VMAVCCUQTALHOB-INIZCTEOSA-N
InChI=1S/C19H19FN2O3/c1-13(23)21-16-10-19(24)22(11-16)17-5-7-18(8-6-17)25-12-14-3-2-4-15(20)9-14/h2-9,16H,10-12H2,1H3,(H,21,23)/t16-/m0/s1
Molecular Formula | C19H19FN2O3 |
Molecular Weight | 342.3642 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sembragiline is a potent, selective, long-acting, and reversible monoamine oxidase B (MAO-B) inhibitor developed as a potential treatment for Alzheimer's disease (AD). Sembragiline was involved in phase II clinical trial to evaluate its the safety, tolerability, and efficacy in patients with moderate AD. In addition, the drug was studied for smoking cessation, however, it failed to demonstrate efficacy during a phase II proof-of-concept trial.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01677754
Participants will receive placebo for RO4602522 orally once daily for 12 months.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:10:44 GMT 2023
by
admin
on
Fri Dec 15 18:10:44 GMT 2023
|
Record UNII |
K3W9672PNJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
676479-06-4
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
CD-103
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
C152331
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
9900
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
1210947-69-5
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
K3W9672PNJ
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
10246762
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707394
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY | |||
|
300000034361
Created by
admin on Fri Dec 15 18:10:44 GMT 2023 , Edited by admin on Fri Dec 15 18:10:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|